KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Research & Development: 2009-2024

Historic Research & Development for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $23.4 million.

  • Rigel Pharmaceuticals' Research & Development rose 18.94% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.2 million, marking a year-over-year increase of 34.91%. This contributed to the annual value of $23.4 million for FY2024, which is 4.66% down from last year.
  • According to the latest figures from FY2024, Rigel Pharmaceuticals' Research & Development is $23.4 million, which was down 4.66% from $24.5 million recorded in FY2023.
  • Over the past 5 years, Rigel Pharmaceuticals' Research & Development peaked at $65.2 million during FY2021, and registered a low of $23.4 million during FY2024.
  • Moreover, its 3-year median value for Research & Development was $24.5 million (2023), whereas its average is $36.1 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Research & Development increased by 13.64% in 2020, and later slumped by 59.31% in 2023.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Research & Development stood at $60.1 million in 2020, then climbed by 8.55% to $65.2 million in 2021, then dropped by 7.61% to $60.3 million in 2022, then tumbled by 59.31% to $24.5 million in 2023, then declined by 4.66% to $23.4 million in 2024.